DAWN
Day One·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 4
Bearish signal 0
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
EPS Beats Expectation
FDA Approved
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DAWN
Day One Biopharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that develops therapies & immno-oncology for cancers
1800 Sierra Point Parkway
Suite 200
Brisbane
CA 94005
--
Day One Biopharmaceuticals, Inc., was incorporated in Delaware as a limited liability company in November 2018. As a commercial-stage biopharmaceutical company, the company focuses on the development of first-of-its-kind or best-in-class medicines for childhood and adult diseases. Day One adopts a search and development strategy to identify, acquire and advance drug programs, and its first commercialized product is tovorafenib, an oral, blood-brain barrier penetrating, highly selective type II RAF kinase inhibitor.
Company Financials
EPS
DAWN has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.29, beating expectations. The chart below visualizes how DAWN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DAWN has released its 2025 Q3 earnings report, with revenue of 39.80M, reflecting a YoY change of -57.56%, and net profit of -19.73M, showing a YoY change of -153.26%. The Sankey diagram below clearly presents DAWN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
